WASHINGTON — The pharmacy benefit manager reforms that President Trump signed into law on Tuesday could lead to employers buying drugs directly from drugmakers, just like the administration is encouraging individual consumers to do through its pending website TrumpRx.
The PBM reforms are part of a Health and Human Services spending bill that Congress passed, and Trump signed, on Tuesday. The law prohibits PBMs from linking their payments to drug prices in Medicare. In the commercial market, the bill would require PBMs to pass through 100% of rebates to employer-sponsored insurance plans. There are also transparency measures for the commercial and Medicare markets.
